Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

So far, Altmetric has seen 14 X posts from 9 X users, with an upper bound of 22,869 followers.

RT @BStuetz: Ct DNA testing in Acalabrutinib Obinutuzumab Venetoclax trial issued 2022 https://t.co/ntKb8YvojY

Ct DNA testing in Acalabrutinib Obinutuzumab Venetoclax trial issued 2022 https://t.co/ntKb8YvojY

ctDNA-based MRD assessment in CLL (Phase 2 LL2-BAAG Study). https://t.co/StZ38oK1Cj https://t.co/6zRRaXY6qR

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.